tbuckley/cabot-search huggingface dataset:
High concordance for MammaPrint 70 genes by RNA next generation sequencing.
Authors: Lorenza Mittempergher, Iris de Rink, Marja Nieuwland, Ron M Kerkhoven, Annuska Glas, Rene' Bernards, Laura van't Veer
Journal: Journal of Clinical Oncology (2012)

3065 Background: The development of new biomarkers often requires fresh frozen (FF) samples. Recently we showed that microarray gene expression data generated from FFPE material are comparable to data extracted from the FF counterpart, including known signatures such as the 70-gene prognosis signature (Mittempergher L et al., 2011). As described by Luo et al (2010) RNA profiling using next generation sequencing (RNA-Seq) is now applicable to archival FFPE specimens. Methods: Technical performance and the comparison between the RNA-Seq 70-gene read-out and the MammaPrint test (Glas et al., 2006) is evaluated in a series of 15 patients (11/15 with matched FFPE/FF material). RNA-Seq was carried out using minor adjustments of the Illumina TruSeq RNA preparation method. RNA sequencing libraries were prepared starting from 100ng of total RNA. Next, the DSN (Duplex-Specific Nuclease) normalization process was used to remove ribosomal RNA and other abundant transcripts (Luo et al, 2010). The libraries were paired-end sequenced on the Illumina HiSeq 2000 instrument with multiplexing of 4 libraries per lane. The resulting sequences were mapped to the human reference genome (build 37) using TopHat 1.3.1(Trapnell et al., 2009). The HTSeq-count tool was used to generate the total number of uniquely mapped reads for each gene. Results: Between 14% and 45% of the total number of reads were assigned to protein-coding genes. The minimum coverage per 1000bp of CDS was 38 reads. The 70 MammaPrint genes were successfully mapped to the RNA-Seq transcripts. We calculated the Pearson correlation coefficient between the centroids of the original good prognosis template (van’t Veer et al., 2002) and the 70-gene read count determined by RNA-Seq of each sample. Predictions based on the 70-gene RNA-Seq data showed a high agreement with the actual MammaPrint test predictions (&gt;90%), irrespective of whether the RNA-seq was performed on FF or FFPE tissue. Conclusions: New generation RNA-sequencing is a feasible technology to assess diagnostic signatures.
INTRA-AORTIC BALLOON PUMP ON IN-HOSPITAL OUTCOMES OF CARDIOGENIC SHOCK: FINDINGS FROM THE HOSPITAL QUALITY MONITORING SYSTEM (HQMS) REGISTRY
Authors: Songyun Chu, Pengfei Sun, Yan Zhang, Jianping Li, Lin Liu, Ying Shi, Haibo Wang, Hu Chen, Yong HUO
Journal: Journal of the American College of Cardiology (2020)
CHOP: haplotype-aware path indexing in population graphs
Authors: Tom Mokveld, Jasper Linthorst, Zaid Al-Ars, Henne Holstege, Marcel J.T. Reinders
Journal: Genome biology (2020)

The practical use of graph-based reference genomes depends on the ability to align reads to them. Performing substring queries to paths through these graphs lies at the core of this task. The combination of increasing pattern length and encoded variations inevitably leads to a combinatorial explosion of the search space. Instead of heuristic filtering or pruning steps to reduce the complexity, we propose CHOP, a method that constrains the search space by exploiting haplotype information, bounding the search space to the number of haplotypes so that a combinatorial explosion is prevented. We show that CHOP can be applied to large and complex datasets, by applying it on a graph-based representation of the human genome encoding all 80 million variants reported by the 1000 Genomes Project.
SINGLE CENTER EXPERIENCE OF IMPELLA ASSISTED HIGH RISK PCI IN PATIENTS WITH SEVERE AORTIC STENOSIS
Authors: Karuppiah Arunachalam, Sharan Rufus Ponniah, Alexis Williams, Kristin Barnes, Tana Ely, Harry D'Agostino, Antonio Sortino, Rizwan Sardar
Journal: Journal of the American College of Cardiology (2020)
Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic
Authors: Frederick G.P. Welt, Pinak B. Shah, Herbert D. Aronow, Anna E. Bortnick, Timothy D. Henry, Matthew W. Sherwood, Michael N. Young, Laura J. Davidson, Sabeeda Kadavath, Ehtisham Mahmud, Ajay J. Kirtane
Journal: Journal of the American College of Cardiology (2020)
SPONTANEOUS CORONARY ARTERY DISSECTION MASQUERADING AS ACUTE CORONARY SYNDROME IN AN ENDURANCE MASTER ATHLETE
Authors: Saman Setareh-Shenas, Roberto Ochoa, Asad Mohammad, Paul Leis, Syed Haider, Jacqueline Tamis-Holland, Eyal Herzog, Alan Rozanski
Journal: Journal of the American College of Cardiology (2020)
Loss to follow-up of cancer patients in the poorest district of the United States.
Authors: Antranik Mangardich, Aleksandra Mamorska-Dyga, Doru Paul, Ghulam Khan, Svetlana Vassel, Linda Gerber, Valentin Guset, Jessica Segni
Journal: Journal of Clinical Oncology (2012)

6123 Background: Loss to follow-up (LFU) of cancer patients is a serious dilemma, and has only been narrowly studied. Lincoln Medical and Mental Health Center (LMMHC) serves South Bronx (SB), the poorest district in the nation. The purpose of this study was to assess rates of LFU and correlate it with age, sex, ethnicity, race, cancer types, and stage at diagnosis. Methods: We collected data from 1,552 patients diagnosed with invasive cancer in LMMHC between 2006-2010. The data collected were age, sex, ethnicity, race, type of cancer, stage, LFU, treatment, and vital status. Results: From the 1,552 patients, roughly 25 % were LFU, with 50% receiving some initial form of treatment. The remaining percentages are shown below (Table). A higher rate of LFU was with patients younger than 65 (OR: 1.38, 95% CI: 1.08-1.76). There was no correlation between sex and LFU. Non-Hispanics were more likely to be LFU compared to Hispanics (OR: 1.39, 95% CI: 1.07 – 1.8). Blacks were more likely to be LFU compared to non-Blacks (OR: 1.43, 95% CI: 1.12–1.82). There was no significance between LFU and stage at diagnosis. Looking at cancer specific data, colon cancer (C) and head and neck cancers (HN) had the highest percentage of LFU (30% each). There was higher LFU rate for C compared to breast cancer (B) (OR: 1.7, 95% CI: 1.03-2.8), prostate cancer (P) (OR: 1.88, 95% CI: 1.18-3.02), and lung cancer (L) (OR: 1.64 95% CI: 0.94- 2.8). HN patients were more likely LFU compared to B (OR: 2.4, 95% CI: 1.13-5.2), P (OR: 2.69, 95 % CI: 1.28-5.68), and L (OR: 2.3, 95% CI: 1.05-5.19) patients. There was no significant difference between C and HN patients in respect to LFU. Conclusions: In the SB, LFU rates are related to age, ethnicity, race, and type of cancer. Younger patients, blacks, non-Hispanics, and those with C and HN cancers were most likely to be LFU, the latter likely due to the lack of a HN surgeon at LMMHC. We hope that with focus on race, ethnicity, and cancer-specific disparities in LFU rates, we will improve the retention rate of our cancer patients in the future. [Table: see text]
ASSESSMENT OF FOOT MICROCIRCULATION BY USING SUPERB MICROVASCULAR IMAGING IN PATIENTS WITH CRITICAL LIMB ISCHEMIA
Authors: Yuta Suto, Wakana Sato, Takayuki Yamanaka, Teruki Sato, Takako Iino, Katsuhito Seki, Tomohito Suzuki, Ken Terata, Kenji Iino, Hiroyuki Watanabe
Journal: Journal of the American College of Cardiology (2020)
Prevalence and impact of hypogonadism in cancer patients with severe muscle wasting in phase IIb enobosarm trial.
Authors: Mitchell S. Steiner, Adrian Dobs, Mary Ann Johnston, Michael L. Hancock, Ronald A. Morton, Shontelle Dodson
Journal: Journal of Clinical Oncology (2012)

e19582 Background: Hypogonadism has been associated with weight loss and poor outcomes in cancer patients. Up to 50% of males with advanced cancer are hypogonadal at presentation or during the course of treatment. Wasting in cancer patients has also been associated with a decline in physical function and performance status and has major public health significance. We conducted a Phase IIb randomized, double blind, placebo controlled, multi-center study to evaluate the effect of enobosarm on muscle wasting and physical function in cancer patients. Methods: Patients (n=159) were randomized to oral enobosarm (1 or 3 mg) or placebo daily for 16 wks. Patients were males &gt;45 y and postmenopausal females, had ≥2% weight loss in the 6 mths prior to randomization, BMI &lt;35 and either NSCLC, colorectal cancer, non-Hodgkins lymphoma, chronic lymphocytic leukemia or breast cancer. We report on the incidence and impact of hypogonadism (T&lt;300 ng/dL) in this population. Results: Baseline testosterone levels were available for 93 of 103 men. 60% of male patients were hypogonadal at randomization. Distribution of hypogonadism was similar across cancers; however hypogonadal men were less likely to complete the study. Baseline T levels were positively correlated with weight loss (r=0.32, p=0.002,) with hypogonadal men demonstrating greater weight loss in the previous six months (median, -9.5%). Baseline physical function as measured by stair climb power was higher among eugonadal males compared to hypogonadal males (84.5 watts vs 70.6 watts; p=0.016). Enobosarm significantly improved physical function in this population regardless of baseline gonadal status (hypogonadal: 18.7%, p=0.0061; eugonadal: 13.2%, p=0.0032). The magnitude of improvement was greater in hypogonadal men. Conclusions: Hypogonadism is common in male cancer patients and is correlated with weight loss and diminished physical function. In this randomized, placebo controlled trial, enobosarm improved physical function in both hypogonadal and eugonadal men despite poorer baseline physical function in hypogonadal patients. These data provide evidence that enobosarm may play an important role in the management of cancer related muscle wasting.
COMPLETE VERSUS CULPRIT-LESION-ONLY REVASCULARIZATION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A COLLABORATIVE META-ANALYSIS OF RANDOMIZED TRIALS
Authors: Kevin R. Bainey, Thomas Engstroem, Pieter Smits, Anthony Gershlick, Stefan K. James, Robert Storey, David Alexander Wood, Roxana Mehran, John Cairns, Shamir R. Mehta
Journal: Journal of the American College of Cardiology (2020)
PERCUTANEOUS CORONARY REVASCULARIZATION IS ASSOCIATED WITH HIGHER EXERCISE CAPACITY AFTER MYOCARDIAL INFARCTION
Authors: Sarah Gorgis, Zachary Demertzis, Kelly Malette, Georgi Fram, Kaitlyn Dobesh, Steven Keteyian, Khaldoon Alaswad, Mir Basir, Clinton Brawner
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF THE PRESENCE OF ATRIAL FIBRILLATION ON OUTCOMES IN PATIENTS PRESENTING TO THE HOSPITAL WITH TRAUMATIC INJURIES
Authors: Peter Wenn, Megan Barber, Amanda Wong, George Yassa, Doreen Olvet, Ofek Hai, Roman Zeltser, Jody Digiacomo, Amgad Makaryus
Journal: Journal of the American College of Cardiology (2020)
HEART FAILURE HOSPITALIZATIONS AND URGENT HEART FAILURE VISITS FOR PATIENTS WITH HEART FAILURE IN A REAL-WORLD POPULATION IN THE US
Authors: Carolyn Lam, Robert Wood, Hector Bueno, Muthiah Vaduganathan, Gabriela Luporini, Alex Chin, Afrah Siddiqui, Elisabeth Sörstadius, Joseph Thomas, Lei Qin
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF RENAL SYMPATHETIC DENERVATION IN ADDITION TO PULMONARY VEIN ISOLATION ON THE RECURRENCE RATE OF ATRIAL FIBRILLATION: A META-ANALYSIS OF RANDOMIZED CONTROL TRIALS
Authors: Barbara Mantilla, Pablo Paz, M Rubayat Rahman, Saif El Nawaa, Mohamed Elmassry, Narut Prasitlumkum, Pattara Rattanawong, Wasawat Vutthikraivit
Journal: Journal of the American College of Cardiology (2020)
VESSEL PREPARATION AND STENT SELECTION ENHANCES STRUT APPOSITION IN NON-COMPLEX LESIONS AS ASSESSED BY OCT
Authors: Joseph Weber, Murtaza Bharmal, Hitoshi Matsukage, Alexandru Marginean, Rohan Kalathiya, John E. Blair, Jonathan D. Paul, Atman P. Shah, Sandeep Nathan
Journal: Journal of the American College of Cardiology (2020)
LEFT VENTRICULAR ASSIST DEVICE VERSUS INTRA AORTIC BALLOON PUMP IN HIGH-RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED TRIALS
Authors: Monil M. Majmundar, Abdullah Zoheb Azhar, Tikal Kansara, Palak Shah, Rajkumar P. Doshi, Tuoyo Mene-Afejuku, Krunalkumar Patel, Harsh Patel, Ferdinand Visco, Gerald Pekler
Journal: Journal of the American College of Cardiology (2020)
Abstract 14839: Transesophageal Echocardiography-Guided Strategy vs Conventional Anticoagulation for Cardioversion of Atrial Fibrillation: An Analysis of Thromboembolic and Bleeding Events From the ENSURE-AF Study
Authors: Jose Luis Merino, Gregory Y Lip, Raffaele De Caterina, Kurt Huber, James Jin, Michael Melino, Shannon M Winters, Andreas Goette
Journal: Circulation (2018)

Introduction: A rapid transesophageal echocardiography (TEE)-guided strategy is an alternative to conventional 3-week anticoagulation before electrical cardioversion (ECV) of atrial fibrillation (A...
INITIAL EXPERIENCE IN TRANSCATHETER CLOSURE OF PATENT DUCTUS ARTERIOSUS WITHOUT FLUOROSCOPY IN INDONESIA
Authors: Radityo Prakoso, Rina Ariani, Yovi Kurniawati, Sisca Natalia Siagian, Aditya Agita Sembiring, Oktavia Lilyasari, Indriwanto Sakidjan, Poppy S. Roebiono, Anna Rahajoe, Olfi Lelya, Ganesja M. Harimurti
Journal: Journal of the American College of Cardiology (2020)
Use of genetic variants in pericyte-driven tumor vessel maturation genes to predict treatment efficacy in mCRC patients treated with FOLFIRI/bevacizumab.
Authors: Nico Benjamin Volz, Wu Zhang, Dongyun Yang, Yan Ning, Sebastian Stintzing, Takeru Wakatsuki, Rita Elie El-Khoueiry, Joseph Ethan Li, Adel Kardosh, Fotios Loupakis, Federica Marmorino, Carlotta Antoniotti, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2013)

3566 Background: Angiogenesis is maintained by the presence of PDGFB (platelet derived growth factor beta) which binds to the receptor, PDGFRB on pericytes, signaling them to stabilize stalk cells adjacent to tip cells. PDGFB signaling by endothelial tip cells promotes proliferation, migration, and stabilization of pericytes which are closely associated with endothelial cells. VEGF driven angiogenesis in response to tumor hypoxia relies on several genes. Previously, studies showed RALBP1, RGS5, and CSPG4 greatly impact the structure of blood vessels during angiogenesis. Recognizing these genes are important in angiogenesis through pericytes, we investigated the correlation between polymorphisms in these genes and clinical outcomes in patients with mCRC treated with FOLFIRI/bevacizumab (BV). Methods: Genomic DNA was extracted from 455 patients’ blood or tissue treated with first-line BV + FOLFIRI and prospectively enrolled in a prospective pharmacogenomic translational study. Median follow up is 24 months and median PFS and OS were 10.5 and 29.9 months, respectively. Eight functionally significant SNPs; RGS5 (rs1056515, rs2661280), PDGFRB (rs2229562, rs2302271), CSPG4 (rs8023621, rs1127648), and RALBP1 (rs10989, rs329007) were analyzed by PCR-based direct sequencing. All candidate SNPs were analyzed for association with tumor response rate (RR), progression free survival (PFS), and overall survival (OS). Results: Four SNPs showed significant results in the univariate analysis of either OS or PFS. PDGFRB rs2302273 remained significant upon multivariate analysis. Univariate analysis of PDGFRB rs2302273 concluded patients with any T (CT/TT) allele were significantly associated with longer PFS compared to those with CC genotypes (median 10.2 vs 11.6 months, HR=0.78 [95%CI: 0.63-.98], p=0.031, log-rank test) which remained significant upon multivariate analysis (HR=0.73 [95% CI: 0.57-0.92], p=0.008, log-rank test). Conclusions: Our results show that the PDGFRB polymorphism rs2302273 may serve as a prognostic marker for the efficacy of FOLFIRI + BV treatment in patients with mCRC. Studies to confirm and update these preliminary findings are ongoing.
Universal Disease Screening and Treatment — The Egyptian Example
Authors: William A. Haseltine
Journal: New England Journal of Medicine (2020)

Interview with Dr. William Haseltine on lessons from Egypt's screening for hepatitis C in the context of its universal disease screening and treatment program. (08:36)Download Few countries have systematically tested and treated their people for the diseases that threaten them most. But a program in Egypt provides an example of how routine testing and treatment for infectious and chronic diseases for an entire country can be achieved.
Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine
Authors: Ling Qian, Kun Chen, Changhong Wang, Zhen Chen, Zhiqiang Meng, Peng Wang
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Oncogenic mutations in NRAS promote tumorigenesis. Although novel anti-NRAS inhibitors are urgently needed for the treatment of cancer, the protein is generally considered “undruggable” and no effective therapies have yet reached the clinic. STK19 kinase was recently reported to be a novel activator of NRAS and a potential therapeutic target for NRAS-mutant melanomas. Here, we describe a new pharmacologic inhibitor of STK19 kinase for the treatment of NRAS-mutant cancers. Experimental Design: The STK19 kinase inhibitor was identified from a natural compound library using a luminescent phosphorylation assay as the primary screen followed by verification with an in vitro kinase assay and immunoblotting of treated cell extracts. The antitumor potency of chelidonine was investigated in vitro and in vivo using a panel of NRAS-mutant and NRAS wild-type cancer cells. Results: Chelidonine was identified as a potent and selective inhibitor of STK19 kinase activity. In vitro, chelidonine treatment inhibited NRAS signaling, leading to reduced cell proliferation and induction of apoptosis in a panel of NRAS-mutant cancer cell lines, including melanoma, liver, lung, and gastric cancer. In vivo, chelidonine suppressed the growth of NRAS-driven tumor cells in nude mice while exhibiting minimal toxicity. Conclusions: Chelidonine suppresses NRAS-mutant cancer cell growth and could have utility as a new treatment for such malignancies.
Prognostic impact of circulating endothelial cell counts in patients with advanced non-small cell lung cancer.
Authors: Nutan Jyothi DeJoubner, Hyunseok Kang, Qunna Li, Wayne A C Harris, Rena Stewart, Alicia Price, Arshed Quyyumi, Scott A. Kono, Suresh S. Ramalingam, Taofeek Kunle Owonikoko, Fadlo Raja Khuri, Edmund K. Waller
Journal: Journal of Clinical Oncology (2012)

e21045 Background: Blood progenitor cells expressing the stem cell marker CD34 have been associated with prognosis in cancer. We hypothesized that non-small cell lung cancer (NSCLC) patients with higher numbers of circulating CD34+ endothelial progenitor cells (CD34+/CD146+/CD45-, CEC) would have worse post-treatment outcomes and patients with more hematopoietic progenitor cells (CD34+/CD45+/CD45dim/CD133+, HPC) would have better outcomes. Methods: Blood samples from patients with advanced NSCLC were analyzed at 3 time points: prior to chemotherapy, after cycle one, and at completion of treatment or progression of disease, in an IRB-approved protocol. CEC, HPC, and immune subsets were measured by flow cytometry optimized for rare event detection. Primary outcomes were progression and death from the time of study entry. Patients were categorized and compared for progression free survival (PFS) and overall survival (OS) based on median cell counts. Differences between groups were tested using log-rank test and Cox regression. Results: A total of 62 patients were enrolled with mean age of 64 (37-87 years). There were 29 deaths after a median follow-up of 8.1 months. 40 patients progressed at a median of 5.4 months. Median numbers of CEC, HPC, and CD4+ T-cells were (0.05/uL, 0.41/uL, and 637/uL, respectively). Lower CEC at baseline was associated with a favorable PFS compared to those with higher counts (median PFS of 7.3 months versus 4.3 months, p=0.049). In a multivariate analysis after adjusting for age, gender, smoking, race, TNM stage, pathology, performance status and CD4 counts at baseline, patients with high CEC had almost 3-fold risk of death (HR=2.70, p=0.04) and disease progression (HR=3.03, p &lt; 0.01) compared with patients with low numbers of CEC. In the same model, patients with fewer CD4+ T cells had &gt; 3 fold risk of death compared with patients with higher numbers (HR=3.79, p=0.01). HPC content was not associated with OS or PFS. Conclusions: In patients with advanced NSCLC, higher CEC and lower CD4 counts at diagnosis are associated with worse outcomes. Higher CEC may serve as a cellular biomarker for extent of disease or tumor biology. Patients with poor T-cell immunity prior to treatment have worse survival.
ASSOCIATION BETWEEN MONOCYTE-LYMPHOCYTE RATIO AND NON-CALCIFIED CORONARY BURDEN IN PSORIASIS
Authors: Binaya Basyal, Heather Teague, Karthik Vedantam, Youssef Elnabawi, Amit Dey, Justin Rodante, Martin Playford, Marcus Y. Chen, Nehal Mehta
Journal: Journal of the American College of Cardiology (2020)
Large-Scale Identification and Time-Course Quantification of Ubiquitylation Events during Maize Seedling De-Etiolation
Authors: Yue-Feng Wang, Qing Chao, Zhe Li, Tian-Cong Lu, Hai-Yan Zheng, Cai-Feng Zhao, Zhuo Shen, Xiao-Hui Li, Bai-Chen Wang
Journal: Genomics Proteomics & Bioinformatics (2019)

Abstract The ubiquitin system is crucial for the development and fitness of higher plants. De-etiolation, during which green plants initiate photomorphogenesis and establish autotrophy, is a dramatic and complicated process that is tightly regulated by a massive number of ubiquitylation/de-ubiquitylation events. Here we present site-specific quantitative proteomic data for the ubiquitylomes of de-etiolating seedling leaves of Zea mays L. (exposed to light for 1, 6, or 12 h) achieved through immunoprecipitation-based high-resolution mass spectrometry (MS). Through the integrated analysis of multiple ubiquitylomes, we identified and quantified 1926 unique ubiquitylation sites corresponding to 1053 proteins. We analyzed these sites and found five potential ubiquitylation motifs, KA, AXK, KXG, AK, and TK. Time-course studies revealed that the ubiquitylation levels of 214 sites corresponding to 173 proteins were highly correlated across two replicate MS experiments, and significant alterations in the ubiquitylation levels of 78 sites (fold change &amp;gt;1.5) were detected after de-etiolation for 12 h. The majority of the ubiquitylated sites we identified corresponded to substrates involved in protein and DNA metabolism, such as ribosomes and histones. Meanwhile, multiple ubiquitylation sites were detected in proteins whose functions reflect the major physiological changes that occur during plant de-etiolation, such as hormone synthesis/signaling proteins, key C4 photosynthetic enzymes, and light signaling proteins. This study on the ubiquitylome of the maize seedling leaf is the first attempt ever to study the ubiquitylome of a C4 plant and provides the proteomic basis for elucidating the role of ubiquitylation during plant de-etiolation.
THE BENEFITS OF INTENSIVE VERSUS STANDARD BLOOD PRESSURE TREATMENT ACCORDING TO FINE PARTICULATE MATTER AIR POLLUTION EXPOSURE: A POST-HOC ANALYSIS OF SPRINT
Authors: Sadeer G. Al-Kindi, David M. Reboussin, Robert D. Brook, Udayan Bhatt, Michael Brauer, William C. Cushman, Heidi Hanson, John Kostis, James Lash, Robert Paine, Kalani Raphael, Steve Rapp, Leonardo Tamariz, Jackson T. Wright, Sanjay Rajagopalan
Journal: Journal of the American College of Cardiology (2020)
Eye Symptoms in a Patient With Prostate Cancer
Authors: Kalevi Kairemo, Aki Kangasmäki, Timo Joensuu, Stefan Seregard
Journal: Clinical Nuclear Medicine (2020)

Abstract A 66-year-old man with castration-resistant prostate cancer was evaluated with 18 F–prostate-specific membrane antigen (PSMA) 1007 PET/CT, which revealed extensive PSMA-positive skeletal metastases in the skull, thorax, spine, pelvis, and extremities. He was then treated 177 Lu-PSMA-617 therapy. Twenty-four-hour SPECT/CT revealed additional activity not seen with 18 F-PSMA adjacent to his left eye. The lesion was biopsied after the first cycle due to pain. This activity was not visible on SPECT/CT after the second treatment cycle, and his eye pain has resolved.